** Shares of biotech Chimerix CMRX.O rise 171.68% to $2.35 after the bell
** Company plans to submit an application seeking FDA's accelerated approval in the U.S. for its drug dordaviprone as a treatment for a type of glioma before year-end
** Adds it will be ready for a U.S. launch as early as Q3 2025
** CMRX is seeking approval of dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma, a type of tumor that forms in the brain
** Up to last close, stock down ~10% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。